The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
The Federal Trade Commission and the State of Nevada are taking action to stop a wide-ranging investment training and business venture scam that has bilked consumers out of more than $1.2 billion. According to the complaint filed by the FTC and the Nevada Attorney General, the scam currently operates as IYOVIA and has also used the brand names IM Mastery Academy, iMarketsLive, and IM Academy (collectively, “IML”).
The complaint alleges the company and its operators use false or baseless earning claims to entice consumers to purchase training on financial topics. They have used similar claims to persuade consumers to buy into IML’s multi-level-marketing business venture, which involves marketing IML’s training services to others. It also alleges that that IML deliberately focused on marketing to young people, including through posts to college social media pages.
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
The Federal Trade Commission will require Synopsys, Inc. and Ansys, Inc., under a proposed consent order, to divest certain assets to resolve antitrust concerns surrounding their $35 billion merger. The proposed consent order settles FTC allegations (link to complaint) that Synopsys’s acquisition of Ansys is anticompetitive across three markets – optical software tools, photonic software tools for designing and simulating photonic devices, and RTL power consumption analysis tools.